Genpact stock reacts to earnings, guidance and buyback update

Genpact (G) is in focus after its second quarter 2026 earnings release, updated earnings guidance and fresh details on its ongoing multi year share repurchase program.

Genpact’s recent 1 month share price return of 16.43% and 3 month share price return of 18.31% point to improving short term momentum. However, the year to date share price return of 25.14% and 1 year total shareholder return of 19.90% show the longer term picture has been weaker.

If Genpact’s latest update has you reassessing your watchlist, this is a good moment to widen the search and check out 20 top founder-led companies

The recent rebound in Genpact after earnings presents a clear choice. Is the current price, following a sharp 1-month move, already fair for the new guidance and buyback progress? Or is patience still worth considering as valuation comes into focus next?

Most Popular Narrative: 18.5% Undervalued

Genpact’s most followed narrative points to a fair value of $42.18 per share, compared with the last close at $34.37. This sets up a clear valuation gap rooted in expectations for AI driven services and ongoing capital returns.

Accelerated client adoption of Genpact's Advanced Technology Solutions particularly in data and AI should drive higher growth and improved margins, as these offerings deliver over twice the revenue per headcount versus legacy services and are expanding at over twice the company's overall rate, pointing toward robust long-term revenue and margin expansion.

Want to see what kind of revenue mix shift would need to happen for that AI and digital focus to support this fair value? The narrative leans heavily on faster growing solution lines, firmer margins, and a different earnings multiple than today. It examines how those moving parts combine into one target price.

Result: Fair Value of $42.18 (UNDERVALUED)

However, Genpact’s story still carries key risks if legacy BPO revenue slows further or if heavier AI investment fails to translate into the expected higher margin deals.

Next Steps

The mixed tone around Genpact’s valuation and AI ambitions creates a clear debate for investors. Consider reviewing the details promptly and forming your own stance using 5 key rewards.

Looking for more investment ideas beyond Genpact?

If Genpact has sharpened your focus, do not stop there. Use the Simply Wall St Screener to surface focused lists of stocks that match what you want next.

• Target potential mispricing by scanning companies that combine solid fundamentals with appealing valuations using the 51 high quality undervalued stocks.
• Strengthen your income watchlist by zeroing in on companies offering higher yields and resilient payouts through the 11 dividend fortresses.
• Prioritise resilience by reviewing companies with sturdier financial positions and dependable fundamentals via the solid balance sheet and fundamentals stocks screener (49 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.